Atherosclerosis Is an Inflammatory Disease which Lacks a Common Anti-inflammatory Therapy: How Human Genetics Can...

Area of Science:

• Cardiovascular Medicine
• Immunology
• Genetics

Background:

• Atherosclerosis is a complex, multifactorial disease driven by risk factors like dyslipidemia and hypertension.
• Inflammation's critical role in atherosclerosis pathogenesis is well-established at molecular and animal model levels.
• Despite extensive research, specific anti-inflammatory therapies for atherosclerosis remained elusive until recently.

Purpose of the Study:

• To review the evolving understanding of inflammation's role in atherosclerosis.
• To highlight the breakthrough in targeting inflammation for cardiovascular event reduction.
• To discuss the contribution of genetic studies in identifying new therapeutic targets.

Main Methods:

• Review of scientific literature on atherosclerosis, inflammation, and genetics.
• Analysis of findings from randomized clinical trials (RCTs), specifically canakinumab.
• Examination of results from genome-wide association studies (GWAS) and their implications.

Main Results:

• The first ad-hoc RCT demonstrated that targeting interleukin-1β with canakinumab significantly lowers cardiovascular events.
• Genome-wide association studies (GWAS) have identified genetic loci linked to inflammatory molecules, reinforcing the inflammation-atherosclerosis connection.
• These genetic findings suggest potential new targets for tailored anti-atherosclerotic therapies.

Conclusions:

• Targeting specific inflammatory pathways represents a viable therapeutic strategy for reducing cardiovascular events in atherosclerosis.
• Genetic research, particularly GWAS, is crucial for uncovering novel molecular targets and understanding atherosclerosis pathogenesis.
• Future whole-exome and whole-genome sequencing studies promise to further refine therapeutic strategies by identifying early-stage intervention targets.